author-photo

Alan David Smith

The Royal Marsden NHS Foundation Trust

12

Papers

29

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Exploring opioid addictions and responsibilities: almost lost in the midst of the Covid-19 pandemic

2021
- Alan David Smith
Show All
- Source
- Cite
- Save
Citations (0)
A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Thrombosis in a population of phase I trial patients.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
791PSEQUENCING OF DOCETAXEL (D) AND ABIRATERONE ACETATE (AA) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)